Search: onr:"swepub:oai:DiVA.org:uu-177563" >
The Clinical Pharma...
The Clinical Pharmacogenomics Implementation Consortium : CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy
-
Wilke, R. A. (author)
-
Ramsey, L. B. (author)
-
Johnson, S. G. (author)
-
show more...
-
Maxwell, W. D. (author)
-
McLeod, H. L. (author)
-
Voora, D. (author)
-
Krauss, R. M. (author)
-
Roden, D. M. (author)
-
Feng, Q. (author)
-
Cooper-DeHoff, R. M. (author)
-
Gong, L. (author)
-
Klein, T. E. (author)
-
- Wadelius, Mia (author)
- Uppsala universitet,Klinisk farmakogenomik och osteoporos
-
Niemi, M. (author)
-
show less...
-
(creator_code:org_t)
- 2012-05-23
- 2012
- English.
-
In: Clinical Pharmacology and Therapeutics. - : Springer Science and Business Media LLC. - 0009-9236 .- 1532-6535. ; 92:1, s. 112-117
- Related links:
-
https://europepmc.or...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Wilke, R. A.
-
Ramsey, L. B.
-
Johnson, S. G.
-
Maxwell, W. D.
-
McLeod, H. L.
-
Voora, D.
-
show more...
-
Krauss, R. M.
-
Roden, D. M.
-
Feng, Q.
-
Cooper-DeHoff, R ...
-
Gong, L.
-
Klein, T. E.
-
Wadelius, Mia
-
Niemi, M.
-
show less...
- Articles in the publication
-
Clinical Pharmac ...
- By the university
-
Uppsala University